Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
L. Yu
Institution:
Sheng Jing Hospital
Observed institution:
Sheng Jing Hospital
ORCID:
0009-0000-5821-865X
Observed ORCID:
0009-0000-5821-865X
OpenAlex ID:
A5037440313
66eP Survival and safety analysis of adebrelimab combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer in real-world settings
2025
·
L. Yu
, C. Guan
, et al.
·
ESMO Open
·
1
PDF
EP08.01-102 Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy
2022
·
L. Yu
, J. Xu
, et al.
·
Journal of Thoracic Oncology
EP08.01-103 Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
2022
·
L. Yu
, J. Xu
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
3
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type